Alzheimer Europe’s 30th Annual Conference #30AEC, which was planned to take place in Bucharest, will now be a virtual conference, under the banner “Dementia in a changing world”
-
-
Top 10 Articles
Top Article: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Abstract Background: Bapineuzumab, a humanized anti-amyloid-beta (A) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.
Methods: The study enrolled 234 patients, randomly… Continue Reading